Today

Agents

Chat

Arena

Discover

More

App

Lilly Q2 Adjusted EPS USD 8.38 Vs. IBES Estimate USD 6.01 - LLY News | Rallies

Lilly Q2 Adjusted EPS USD 8.38 Vs. IBES Estimate USD 6.01

LLY•2026-08-05

Lilly reports Q2 results and raises full-year outlook

Aug. 5 (Reuters) - Lilly Q2 Mounjaro revenue USD 9,943 million.

Q2 revenue USD 22,974 million vs. IBES estimate USD 20,725 million
Q2 Zepbound revenue USD 4,928 million
Q2 EPS USD 7.94
Outlook FY revenue USD 85,000-87,000 million
Outlook FY adjusted EPS USD 35.5-36.5
Q2 worldwide Mounjaro revenue increased 91% to $9.9 billion

Related News

Holley Performance Brands slightly misses Q2 sales estimates, reiterates 2026 guidance

HLLY•2026-08-05

Spyre Therapeutics Inc <SYRE.O>: Raymond James raises target price to $121 from $88

SYRE•2026-08-05

Qualys Inc <QLYS.O>: Morgan Stanley raises target price to $130.00 from $115.00

QLYS

•

2026-08-05

Certara Inc <CERT.O>: Morgan Stanley cuts target price to $9.00 from $10.00

CERT•2026-08-05

Advanced Micro Devices <AMD.O>: Morgan Stanley raises target price to $465.00 from $410.00

AMD•2026-08-05